XIENCE(TM) V Drug Eluting Stent from Abbott Reduces Major Adverse Cardiac Events in Small Vessel Patients Out to One Year
Barcelona, Spain (ots/PRNewswire) - - Data from SPIRIT II and III Clinical Trials Also Show Improvement in Vessel Renarrowing with XIENCE V Compared to TAXUS in Patients with Small Vessels Data presented today from an independent pooled subset analysis of Abbott's SPIRIT II and SPIRIT III clinical ...